Biotech grants in Israel
Explore Biotech grants for companies in Israel. This list brings together funding for drug discovery, diagnostics, cell and gene therapy, biomanufacturing and life-science research from Israeli innovation agencies, research funders and foundations, international programs open to applicants in Israel, and competitions any company can enter, with the deadline, award size and eligibility on every listing. Grants aimed at Biotech in Israel come first.
Showing 193-216 of 576 grants
FARA Clinician Scientist Development Award
FARA · United States
Supports early-career clinician scientists with protected salary time to launch Friedreich's ataxia translational research careers.
FARA General Research Grant
FARA · United States
Funds Friedreich ataxia research on disease mechanisms and translational targets.
FARA Postdoctoral & Graduate Training Awards
FARA · United States
Supports postdoctoral and graduate researchers entering new Friedreich ataxia studies.
Advanced Development of Informatics Technologies for Cancer Research and Management
NIH · United States
Funds the enhancement of a cancer informatics tool that has cleared prototyping, shows real promise, and has not yet been widely adopted.
Sustained Support for Informatics Technologies for Cancer Research and Management
NIH · United States
Funds the running costs and continued relevance of a cancer informatics tool that researchers already depend on.
Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases
FDA · United States
Funds foreign and domestic entities running rare-disease clinical trials through FDA orphan products research grants.
GREGoRi Innovation Projects
NIH · United States
Funds a genuinely new experimental or computational approach to finding the cause of a rare genetic disorder, where the current state of the art falls short.
Xcelerate Champion of Innovation
WHX Tech · United Arab Emirates
Pays an equity-free cash prize to the top healthcare startup pitching live at WHX Tech's Xcelerate competition in Dubai.
Developing novel theory and methods for understanding the genetic architecture of complex human traits (R01)
NIH · United States
Funds theory and method development on how genetic and non-genetic factors together produce variation in complex traits, tested against large existing datasets.
Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01)
NIH · United States
Funds new analysis of clinical, genomic, environmental and registry data that already exists, to sharpen who is at risk of cancer and what happens to them.
Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research
NIH · United States
Funds the development and hard technical validation that turns a working cancer research technology into one other laboratories will actually adopt.
Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research
NIH · United States
Funds proof-of-concept work on a genuinely new tool, assay, platform or instrument for characterising cancer cells or handling biospecimens.
Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21)
NIH · United States
Funds the same reanalysis of already-collected cancer data on a smaller, exploratory footing, for teams that do not need a full research project award.
Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant
NIH · United States
Funds exploratory studies of the ethical, legal and social consequences of human genetics, especially where a technology or a use of genomic data is new.
Ethical, Legal and Social Implications (ELSI) Research
NIH · United States
Funds a full research project on the ethics, law and social effects of human genetics — and refuses to review an application with no diverse-perspectives plan.
Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD)
NIH · United States
Funds one bundled run from first-in-human through phase 2a for a dementia drug that works on something other than amyloid or tau.
Developing novel theory and methods for understanding the genetic architecture of complex human traits (R21)
NIH · United States
Funds the exploratory version of the same theory-and-methods work on complex trait variation, for ideas that need testing before a larger project is justified.
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01)
NIH · United States
Funds work on how GLP-1 and related drugs change cancer risk — raising it for some cancers, lowering it for others.
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21)
NIH · United States
Funds smaller, higher-risk work on how GLP-1 and related drugs change cancer risk. No clinical trial in this version.
National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis
NIH · United States
Funds a Phase 0, I or II cancer trial that the investigator designed, inside one of six named National Cancer Institute programme areas.
NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders
NIH · United States
Funds Phase I trials for heart, lung, blood and sleep disorders — and pays for the final preclinical work needed to start one.
Minor Use Minor Species Development of Drugs
FDA · United States
Funds the safety and effectiveness testing costs of getting a designated new animal drug through FDA approval.
BRAIN Initiative: Development and Validation of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in the Brain
NIH · United States
Funds new genetic or non-genetic tools that deliver genes, proteins or chemicals to specific brain cells or circuits, with validation built in.
Development and Validation of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in the Brain
BRAIN Initiative · United States
Funds new methods to study brain cells and circuits with tools for deeper neural research.